Clinical trial

Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis

NCT07754617

Study summary

ClinicalTrials.gov

Different Treatment Frequencies for Hepatic Fibrosis Due to Schistosomiasis

Design: INTERVENTIONAL · Status: NOT YET RECRUITING · Phase: PHASE2, PHASE3

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Unmapped registry intervention Praziquantel 40 mg/kg per dose given once annually Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Praziquantel 40 mg/kg given three times per year Find medicine records · Find other trials using this name

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-11-01

PhasePHASE2 / PHASE3

Conditions

Schistosomiasisverified · MONDO: schistosomiasis

Schistosoma Mansoniunresolved

Liver Fibrosisunresolved

Portal Hypertensionverified · MONDO: portal hypertension

Interventions

Praziquantel 40 mg/kg per dose given once annuallyDRUG

Praziquantel 40 mg/kg given three times per yearDRUG

Sponsors & collaborators

Rhode Island Hospitallead sponsor

National Institute of Allergy and Infectious Diseases (NIAID)collaborator

MRC/UVRI and LSHTM Uganda Research Unitcollaborator

Mapped research locations

EntebbeUganda1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07754617 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.